Octapharma Gains FDA Supplemental Approval for NUWIQ Recombinant Factor VIII in Hemophilia A

Recombinant protein manufacturers operating under 21 CFR Part 211 and biologics-specific GMP frameworks should note that Octapharma USA, Inc. received updated FDA approval documentation for NUWIQ (Antihemophilic Factor, Recombinant) in late December 2024, with the agency publishing the approval letter and clinical pharmacology memorandum on December 26, 2024. The update reinforces the regulatory standing of a product that sits at the intersection of biologics manufacturing complexity and post-approval compliance obligations.

NUWIQ carries indication for pediatric and adult patients with Hemophilia A across three clinical contexts: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce bleeding frequency. The product is explicitly not indicated for von Willebrand disease, a boundary that carries labeling and pharmacovigilance implications for QA teams managing post-market surveillance programs.

The December 2024 documentation package includes a clinical pharmacology memorandum, a full clinical review, and a statistical review, all now part of the public approval record under STN BL 125555. For QA directors and regulatory affairs leads, the availability of these supporting documents provides a reference baseline for comparability assessments, process validation alignment, and any future supplement submissions involving manufacturing changes to recombinant Factor VIII production.

Read against current ICH Q10 expectations for pharmaceutical quality systems, the maintained and updated approval profile signals that FDA continues to apply rigorous post-approval scrutiny to recombinant blood coagulation products. Facilities producing similar biologics should treat this approval record as a live benchmark for sterility assurance protocols, comparability study design, and change control documentation standards.

The clinical pharmacology memorandum dated December 18, 2024 and the approval letter dated December 26, 2024 are both accessible through FDA's approved blood products database, giving compliance teams direct access to the evidentiary package underpinning the current label.